Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

IPO

- PMLiVE

Roche’s PD-L1 inhibitor Tecentriq approved in China for SCLC

Solidifies immunotherapy drug's dominance in the setting

- PMLiVE

Green Valley’s algae-based Alzheimer’s drug to undergo global clinical trials

Gained conditional approval in China in November

- PMLiVE

Boehringer Ingelheim to manufacture first biologic in China under new reforms

German pharma will manufacture BeiGene's PD-1 inhibitor

- PMLiVE

China updates drug reimbursement list, agrees price cuts

Drugs added include AbbVie's Humira and Roche's Perjeta

- PMLiVE

Merck’s Keytruda picks up third approval for NSCLC in China

New indication as a first-line treatment in combination with chemotherapy

Novartis day

Novartis changes focus in Shanghai from early research to drug development

Swiss pharma switches focus of $1bn R&D institute

- PMLiVE

China okays Green Valley’s algae-based drug for Alzheimer’s drug

Due to start phase 3 trials in the US and Europe next year

China: How to strategise and win in the world’s fastest changing healthcare market

In this paper, experts Marc Yates, Pei Li Teh and Brett Gardiner discuss the China healthcare reforms which affect pharma and propose how to build the market understanding required to launch...

Research Partnership

China flag thumb

Amgen buys BeiGene stake for $2.7bn to aid push into China

China's oncology market forecast to nearly double in size by 2026

AstraZeneca AZ

AZ reports growth again in Q3, driven by oncology and China sales

Company has also returned to growth in Europe

- PMLiVE

Merck KGaA launches €13m seed fund for Chinese startups

Company also officially opens innovation hub in Shanghai

- PMLiVE

Chi-Med cues up two more regulatory filings in cancer

Hong Kong based firm reports strong sales in first marketed product

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links